Puma Biotechnology, Inc.
PBYI
$3.00
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -18.15% | 43.53% | -13.72% | -17.07% | 9.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.15% | 43.53% | -13.72% | -17.07% | 9.90% |
| Cost of Revenue | -42.77% | 119.04% | -10.11% | -18.84% | 44.47% |
| Gross Profit | -5.64% | 20.11% | -14.72% | -16.48% | -2.01% |
| SG&A Expenses | -15.02% | -26.24% | 2.08% | -3.27% | -27.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.46% | 23.00% | -0.83% | -4.84% | -1.57% |
| Operating Income | -13.34% | 157.18% | -144.54% | -152.67% | 92.40% |
| Income Before Tax | -4.42% | 242.95% | -279.46% | -396.83% | 341.04% |
| Income Tax Expenses | -1,418.47% | 36.62% | 102.14% | 49.66% | 82.31% |
| Earnings from Continuing Operations | 57.36% | 250.53% | -313.03% | -443.68% | 318.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.36% | 250.53% | -313.03% | -443.68% | 318.84% |
| EBIT | -13.34% | 157.18% | -144.54% | -152.67% | 92.40% |
| EBITDA | -11.50% | 117.76% | -90.62% | -91.74% | 74.92% |
| EPS Basic | 52.58% | 239.84% | -306.15% | -433.00% | 310.54% |
| Normalized Basic EPS | -11.63% | 232.66% | -273.79% | -387.92% | 155.88% |
| EPS Diluted | 58.48% | 241.67% | -306.15% | -433.33% | 296.75% |
| Normalized Diluted EPS | -11.39% | 233.63% | -275.49% | -390.73% | 153.56% |
| Average Basic Shares Outstanding | 3.14% | 3.13% | 3.28% | 3.33% | 3.90% |
| Average Diluted Shares Outstanding | 2.85% | 2.83% | 2.31% | 2.19% | 4.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |